Intelligence · Patents
Patents expiring in 2036
Annual patent cliff calendar for 2036 — US pharmaceutical patents by expiration date.
- Patents
- 1,428
Quick answer
1,428 indexed pharmaceutical patents have expiration dates in 2036. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9296701
DNA-PK inhibitors
granted -
US 9297015
Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety
granted -
US 9296776
Substituted nucleoside derivatives with antiviral and antimicrobial properties
granted -
US 9296798
Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
granted -
US 9296730
Aurora kinase inhibitors
granted -
US 9297009
UNA oligomers targeting micro-RNA for therapeutics
granted -
US 9296729
Low molecular weight thyroid stimulating hormone receptor (TSHR) agonists
granted -
US 9296774
Halogenated dideoxy sugar derivates, preparation method and application thereof
granted -
US 9296790
Methods and compositions for protein delivery
granted -
US 9296746
Heterocyclic compound
granted -
US 9296693
Acyl piperidine inhibitors of soluble epoxide hydrolase
granted -
US 9296694
Azacyclic compounds
granted -
US 9296681
Cycloalkylmethylamines
granted -
US 9295754
Noggin inhibitory compositions for ossification and methods related thereto
granted -
US 9295715
Minimizing intestinal dysfunction
granted -
US 9295683
Omega-3 phospholipid supplements for improved brain maturity
granted -
US 9295659
High dose extended-release potassium citrate wax matrix tablet
granted -
US 9295645
Compositions comprising buprenorphine
granted -
US 9295639
Treating critically ill patients with intravenous ibuprofen
granted -
US 9295629
WNT family-derived peptides and use thereof
granted -
US 9297008
Small activating RNA molecules and methods of use
granted -
US 9295678
Nitrated lipids and methods of making and using thereof
granted -
US 2016089368
TREATMENT OF MASTOCYTOSIS WITH MASITINIB
granted -
US 9302120
Spiro-oxindole MDM2 antagonists
granted -
US 9301927
Para-xylene films and therapeutic uses thereof
granted -
US 9303260
UNA duplex oligomers for therapeutics
granted -
US 9303258
Method and compositions comprising small RNA agonist and antagonists to modulate inflammation
granted -
US 9303087
Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof
granted -
US 9303080
Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
granted -
US 9303077
Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity
granted -
US 9304124
Compact multifunctional ligand to enhance colloidal stability of nanoparticles
granted -
US 9303061
Spiro compounds as Hepatitis C virus inhibitors
granted -
US 9303045
5-HT3 receptor antagonists
granted -
US 9303053
Compositions and methods to treat cardiac diseases
granted -
US 9303064
Peptide inhibiting matrix metalloproteanases activity and use thereof
granted -
US 9303042
Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors
granted -
US 9303000
Olefin containing nuclear transport modulators and uses thereof
granted -
US 9302981
Synthesis, methods of using, and compositions of cycloalkylmethylamines
granted -
US 9303002
Compounds and their methods of use
granted -
US 9302085
Methods and compositions for facilitating arterial access
granted -
US 9302010
Stable formulations for parenteral injection of peptide drugs
granted -
US 9301976
Compositions comprising perivascular stem cells and nell-1 protein
granted -
US 9301947
Ryanodine receptor inhibitors for treatment of T-cell mediated disorders
granted -
US 9302002
Etanercept formulations stabilized with combinations of sugars and polyols
granted -
US 9301960
Methods for inhibiting redox-sensitive GTPases
granted -
US 9302013
Active principle for mitigating undesired medical conditions
granted -
US 9303066
Treatments for gastrointestinal disorders
granted -
US 9301509
Genetically modified mice and engraftment
granted
Frequently asked questions
How many pharma patents expire in 2036?
1,428 published patents in our USPTO index have expiration dates falling in calendar year 2036.